Published in Nature on July 25, 2002
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.56
Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett (2005) 2.22
Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep (2003) 2.16
Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther (2005) 1.81
RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol (2005) 1.68
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother (2009) 1.60
Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther (2006) 1.48
Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA (2013) 1.24
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther (2012) 1.19
Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells. Nat Protoc (2013) 1.11
Consensus siRNA for inhibition of HCV genotype-4 replication. Virol J (2009) 1.10
Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods (2011) 1.03
Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach. Mol Ther (2011) 0.95
Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells. Nucleic Acid Ther (2012) 0.87
A small interfering RNA targeting coxsackievirus B3 protects permissive HeLa cells from viral challenge. J Virol (2005) 0.85
Fabrication of Polyvalent Therapeutic RNA Nanoparticles for Specific Delivery of siRNA, Ribozyme and Drugs to Targeted Cells for Cancer Therapy. IEEE NIH Life Sci Syst Appl Workshop (2009) 0.82
Inhibition of West Nile Virus replication by retrovirus-delivered small interfering RNA in human neuroblastoma cells. J Med Virol (2008) 0.77
Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells. Virology (2015) 0.76
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Short interfering RNA confers intracellular antiviral immunity in human cells. Nature (2002) 5.27
Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. Mol Cell (2009) 4.54
Alu element-mediated gene silencing. EMBO J (2008) 3.22
Genomewide characterization of non-polyadenylated RNAs. Genome Biol (2011) 2.92
Long noncoding RNAs with snoRNA ends. Mol Cell (2012) 2.71
Genome-wide analysis of coordinate expression and evolution of human cis-encoded sense-antisense transcripts. Trends Genet (2005) 2.04
Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. Stem Cells (2011) 1.90
Molecular basis for an attenuated cytoplasmic dsRNA response in human embryonic stem cells. Cell Cycle (2010) 1.71
Effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev (2004) 1.57
Decoding the function of nuclear long non-coding RNAs. Curr Opin Cell Biol (2010) 1.54
Gene regulation by SINES and inosines: biological consequences of A-to-I editing of Alu element inverted repeats. Cell Cycle (2008) 1.42
Evidence for a preferential targeting of 3'-UTRs by cis-encoded natural antisense transcripts. Nucleic Acids Res (2005) 1.37
Evidence for variation in abundance of antisense transcripts between multicellular animals but no relationship between antisense transcriptionand organismic complexity. Genome Res (2006) 1.35
Human antisense genes have unusually short introns: evidence for selection for rapid transcription. Trends Genet (2005) 1.35
Vigilins bind to promiscuously A-to-I-edited RNAs and are involved in the formation of heterochromatin. Curr Biol (2005) 1.34
Antisense starts making more sense. Nat Biotechnol (2003) 1.34
Long noncoding RNAs in mammalian cells: what, where, and why? Wiley Interdiscip Rev RNA (2010) 1.19
Retention and repression: fates of hyperedited RNAs in the nucleus. Curr Opin Cell Biol (2005) 1.07
SINEs point to abundant editing in the human genome. Genome Biol (2005) 0.97
ADAR editing wobbles the microRNA world. ACS Chem Biol (2007) 0.89
Gene regulation by sense-antisense overlap of polyadenylation signals. RNA (2009) 0.85
Innate immunity in pluripotent human cells: attenuated response to interferon-β. J Biol Chem (2013) 0.84
RNA processing in the polyoma virus life cycle. Front Biosci (Landmark Ed) (2009) 0.83
Nuclear Editing of mRNA 3'-UTRs. Curr Top Microbiol Immunol (2012) 0.80
On the mechanism of induction of heterochromatin by the RNA-binding protein vigilin. RNA (2008) 0.80
Methods for the analysis of adenosine-to-inosine editing in RNA. Methods Mol Biol (2004) 0.79
Unleash the messenger. Nat Cell Biol (2005) 0.75